Takeaways from the KOL event
Abivax hosted a virtual KOL event yesterday featuring i) a discussion on the unmet medical need and current treatment landscape for patients with UC, and ii) a review of Obefazimod's phase 2b data as well as iii) the phase 3 trial design for the treatment of moderate-to-severe UC and its strategy t
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.